Skip to main content
. 2021 Jun 11;39(30):3377–3390. doi: 10.1200/JCO.21.00086

FIG 1.

FIG 1.

Flow diagram of patient inclusion. A total of 3,334 patients with HR-NB were enrolled in the HR-NBL1 trial from 188 centers. Among these, 2,350 patients were not included in this study, either because no contributive tumor material was available, or because these was no FU data, or both. Thus, 1,092 patients from 132 centers were included in this study. aClonal level: > 20% MAF. bSubclonal level: MAF 0.1%-20%. FU, follow-up; HR-NB, high-risk neuroblastoma; MAF, mutated allele fraction.